Sunday August 20, 2017 09:08

Heathcare Press Release : 26 Jul 2017

Pan Rajdhevee Group Unveils Pan Acne Formula Three Lotion, the Worlds First Acne Solution Innovation, with the #ShockAcneIn3Days Campaign Heathcare—26 Jul 17

Pan Rajdhevee Group, Thailand's leading cosmeceutical brand, pushed forth in continuously developing skincare innovations and introduced "Pan Acne Formula Three Lotion," the ultimate acne solution without relying on any medicine. The solution targets

ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings Heathcare—26 Jul 17

LONDON--26 Jul--PRNewswire/InfoQuest
DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens

ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from DAWNING. This is a non-inferiority study conducted to compare second-line treatment of the protease inhibitor-sparing regimen of dolutegravir and 2 nucleoside reverse transcriptase inhibitors (NRTIs), with a current WHO-recommended regimen of lopinavir/ritonavir and 2 NRTIs in HIV-1-infected adults. Results are being presented at the International AIDS Society congress in Paris.

(Logo: http://photos.prnewswire.com/prnh/20160223/336449LOGO )

The study's Independent Data Monitoring Committee (IDMC) noted significant and clinically-relevant differences between treatment arms in favour of dolutegravir and recommended that the boosted lopinavir treatment arm be discontinued. Participants receiving lopinavir/ritonavir were offered the opportunity to switch to a regimen with dolutegravir as the core agent, if considered appropriate by the investigator.

The primary endpoint was the proportion of patients with plasma HIV-1 RNA <50 copies per millilitre (c/mL) at week 48. The 24-week interim data showed an 8

Unique concept of MDx, Seegene Random Access System, announced at AACC Heathcare—26 Jul 17

Seegene Inc. (096530.KQ), the world's leading developer of multiplex molecular diagnostics technologies and assays, is to present its unique Seegene Random Access System (the "System") at the 69th AACC Annual Clinical Lab Expo in San Diego, CA, from July